Raymond James startet Coverage für Milestone Pharmaceuticals mit "Strong Buy" und sieht fast 200 % Kurspotenzial
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)